How similar is your antibody to clinical-stage therapeutics?
For a full description of the profiler, or if you use this software, please refer to: Raybould MIJ, et al. Five Computational Developability Guidelines for Therapeutic Antibody Profiling. PNAS. (2019)
Please cite our paper "Five Computational Developability Guidelines for Therapeutic Antibody Profiling" if making use of these datasets.
NB: The PSH value has shifted upwards for both CSTs and natural antibodies with a recent code change to include previously omitted residues in the periphery of the CDR vicinity. This code change came into effect on 4th May 2021, please recalculate TAP metrics for your antibodies if interpreting relative to these reference values. See the new Vander Heiden natural antibody values here [as an indication, PSH 95th percentile: 190.27 (CSTs: 173.52), PSH 100th percentile: 248.38 (CSTs: 208.67)]:
|Property||Amber Region (4th May 2021)||Red Region (4th May 2021)|
|Total CDR Length (L)||37 ≤ L ≤ 43||L < 37|
|55 ≤ L ≤ 63||L > 63|
|Patches of Surface Hydrophobicity (PSH)||89.9 ≤ PSH ≤ 116.3||PSH < 89.9|
|173.52 ≤ PSH ≤ 208.67||PSH > 208.67|
|Patches of Positive Charge (PPC)||1.26 ≤ PPC ≤ 3.74||PPC > 3.74|
|Patches of Negative Charge (PNC)||1.84 ≤ PNC ≤ 4.25||PNC > 4.25|
|Structural Fv Charge Symmetry Parameter (SFvCSP)||-19.50 ≤ SFvCSP ≤ -5.7||SFvCSP < -19.50|
Please visit Thera-SAbDab to access our latest CST sequence data.